Salīdzināt metodes
Apskatiet izvēlētās metodes blakus; rindas, kas atšķiras, ir izceltas.
| Mini-Mental State Examination× | Alcheimera slimības novērtēšanas skala-kognitīvā× | |
|---|---|---|
| Nozare | Neiropsiholoģija | Neiropsiholoģija |
| Saime | Process / pipeline | Process / pipeline |
| Izcelsmes gads≠ | 1975 | 1984 |
| Autors≠ | Marshall Folstein | William Rosen |
| Tips≠ | Clinician-administered cognitive screening instrument | Clinician-administered cognitive scale for Alzheimer's disease |
| Pirmavots≠ | Folstein, M. F., Folstein, S. E., & McHugh, P. R. (1975). Mini-mental state: A practical method for grading the cognitive state of patients for the clinician. Journal of Psychiatric Research, 12(3), 189-198. DOI ↗ | Rosen, W. G., Mohs, R. C., & Davis, K. L. (1984). A new rating scale for Alzheimer's disease. American Journal of Psychiatry, 141(11), 1356-1364. DOI ↗ |
| Citi nosaukumi≠ | MMSE, Folstein MMSE | ADAS-Cog, ADAS-Cog14, ADAS-Cog13 |
| Saistītās | 5 | 5 |
| Kopsavilkums≠ | The Mini-Mental State Examination (MMSE) is a brief, 30-point screening instrument developed by Folstein, Folstein, and McHugh in 1975 to assess cognitive function in clinical settings. It is designed to detect cognitive impairment and monitor cognitive decline over time, particularly in older adults and patients with suspected dementia. The MMSE remains one of the most widely used cognitive screening tools in primary care, neurology, and geriatric medicine worldwide. | The Alzheimer's Disease Assessment Scale-Cognitive (ADAS-Cog) is a clinician-administered cognitive assessment instrument designed specifically to measure cognitive decline in Alzheimer's disease. Developed by Rosen, Mohs, and Davis in 1984 and published in the American Journal of Psychiatry, the ADAS-Cog has become the gold standard outcome measure in pharmaceutical trials of antidementia drugs. It is sensitive to disease progression and capable of detecting cognitive change over periods as brief as 6–12 months. |
| ScholarGateDatu kopa ↗ |
|
|